Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 2/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | DDO | Q99489 | 1/20 | 0.34 |
| ▸ | CIT | O14578 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15645163 | 0.72 | CHUK (0.44) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL16908345 | 0.70 | IKBKB (0.35) | IKBKBCHUK | |
| SCHEMBL16908233 | 0.70 | NUDT1 (0.42) | IKBKBCHUK | |
| SCHEMBL29375488 | 0.67 | IKBKB (0.38) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL22502463 | 0.67 | IKBKB (0.38) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL22524176 | 0.65 | RET (0.40) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL30248822 | 0.65 | RET (0.40) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL2987800 | 0.64 | IKBKB (0.58) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL17394757 | 0.64 | AURKA (0.36) | IKBKBCHUKCSNK1DMAPK14CIT | |
| SCHEMBL17538627 | 0.64 | CSNK1D (0.38) | IKBKBCHUKCSNK1DMAPK14CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | IKBKB 636/4885CHUK 266/4885CSNK1D 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.